Jones-Hall Yava L, Nakatsu Cindy H
a Comparative Pathobiology Department, Purdue University , West Lafayette , IN , USA.
b Department of Agronomy , Purdue University , West Lafayette , IN , USA.
Gut Microbes. 2016;7(1):58-62. doi: 10.1080/19490976.2015.1121364.
Inflammatory bowel disease (IBD), comprised of Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of multifactorial etiology and risk factors. Currently, one of the most effective treatments for IBD is the use of Tumor Necrosis Factor (TNF) functional inhibitor drugs, however, this treatment can cause adverse reactions and has a relatively large percentage of incomplete or non-responders. This lack of response may be related to differences in patients' gut microbiomes prior to and after disease initiation or treatment. Recent observations in our lab using a rodent model of IBD support the theory that TNF drives acute colitis, but also that the microbiome differs in association with TNF production and colitis severity. Studies such as this and others provide new insights into host-microbiome interactions associated with colitis that can lead to new therapies to prevent or treat the disease.
炎症性肠病（IBD）包括克罗恩病和溃疡性结肠炎，是一种病因和风险因素多方面的慢性炎症性疾病。目前，IBD最有效的治疗方法之一是使用肿瘤坏死因子（TNF）功能抑制剂药物，然而，这种治疗可能会引起不良反应，并且有相对较大比例的不完全应答者或无应答者。这种缺乏应答可能与疾病发生或治疗前后患者肠道微生物群的差异有关。我们实验室最近使用IBD啮齿动物模型的观察结果支持了这样一种理论，即TNF驱动急性结肠炎，而且微生物群在与TNF产生和结肠炎严重程度相关方面存在差异。诸如此类的研究为与结肠炎相关的宿主-微生物群相互作用提供了新的见解，这可能会带来预防或治疗该疾病的新疗法。
